Blog
RSS FeedPosted by Michael Wonder on 15 Jan 2026
Ontario pioneers access to treatment for severe alopecia areata with Lilly's Olumiant
14 January 2026 - Eli Lilly Canada announced today that Ontario leads the way as the first province to add Olumiant ...
Posted by Michael Wonder on 09 Dec 2025
Saskatchewan adds Capvaxive to publicly funded adult immunisation program
8 December 2025 - Merck announced today that the province of Saskatchewan has added Capvaxive, a 21 valent pneumococcal conjugate vaccine, ...
Posted by Michael Wonder on 05 Dec 2025
New data on drug approvals and reimbursement recommendations in Canada
27 November 2025 - We have published new data about Canada’s pharmaceutical landscape, including data about drug submissions filed with ...
Posted by Michael Wonder on 21 Nov 2025
Merck Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Winrevair (sotatercept)
20 November 2025 - Merck announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for Winrevair (sotatercept). ...
Posted by Michael Wonder on 09 Nov 2025
Rhythm Pharmaceuticals announces public reimbursement for Imcivree (setmelanotide) in Canada in five provinces and under the Federal Non-Insured Health Benefits Program
5 November 2025 - Rhythm Pharmaceuticals today announced that it has entered into Product Listing Agreements in the provinces of Ontario, ...
Posted by Michael Wonder on 16 Sep 2025
AbbVie's Vraylar (cariprazine) now publicly reimbursed in Alberta
15 September 2025 - AbbVie announced today that Alberta has listed Vraylar (cariprazine) on its Health Drug Formulary. ...
Posted by Michael Wonder on 10 Sep 2025
Enhanced access to generalised myasthenia gravis treatments: UCB Canada secures pCPA agreements for Zilbrysq and Rystiggo
9 September 2025 - Important milestone brings eligible Canadians living with generalised myasthenia gravis one step closer to accessing innovative ...
Posted by Michael Wonder on 10 Sep 2025
Pfizer's Prevnar 20 selected for pneumococcal public immunisation program in British Columbia
9 September 2025 - Today, Pfizer Canada announced that its 20 valent pneumococcal conjugate vaccine, Prevnar 20, has been selected for ...
Posted by Michael Wonder on 31 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion in Ontario
29 August 2025 - Roche Canada is pleased to announce today that Vabysmo (faricimab injection) is now publicly funded for ...
Posted by Michael Wonder on 22 Aug 2025
Leqvio advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance
21 August 2025 - Eligible Canadian patients with heterozygous familial hypercholesterolaemia are one step closer to publicly funded access to ...
Posted by Michael Wonder on 16 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion and pre-filled syringe in Quebec
15 August 2025 - Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively ...
Posted by Michael Wonder on 30 Jul 2025
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx for hidradenitis suppurativa (
23 July 2025 - Following this important milestone, Cosentyx has been listed in Québec. ...
Posted by Michael Wonder on 27 Mar 2025
ViiV Healthcare announces reimbursement for Apretude for HIV-1 pre-exposure prophylaxis under the Non-Insured Health Benefits (NIHB) Program
25 March 2025 - ViiV Healthcare is pleased to announce that Apretude (cabotegravir tablets and extended release injectable suspension) is ...
Posted by Michael Wonder on 01 Mar 2025
Bimzelx (bimekizumab) negotiations with pCPA concluded successfully following positive CDA and INESSS recommendations for adults with active psoriatic arthritis and adults with active ankylosing spondylitis
28 February 2025 - Positive CDA and INESSS reimbursement recommendations are an important step towards public access to Bimzelx, the first ...
Posted by Michael Wonder on 14 Feb 2025
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance successfully finalise negotiations for Apretude for HIV-1 pre-exposure prophylaxis
13 February 2025 - ViiV Healthcare is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance ...